Free Trial
NASDAQ:MGRX

Mangoceuticals Q2 2026 Earnings Results & Report

Mangoceuticals logo
$0.34 -0.03 (-7.70%)
As of 01:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Mangoceuticals reported Q2 2026 earnings on August 13, 2026. The company reported EPS of -$0.09, while revenue was $0.08 million.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Mangoceuticals EPS Results

Actual EPS
-$0.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mangoceuticals Revenue Results

Actual Revenue
$0.08 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Mangoceuticals Q2 2026 Earnings FAQ

Mangoceuticals (NASDAQ:MGRX) reported earnings of -$0.09 per share for Q2 2026. The report was announced on Thursday, August 13, 2026.

Mangoceuticals reported revenue of $0.08 million for Q2 2026.

Mangoceuticals Earnings Headlines

Mangoceuticals (NASDAQ: MGRX) closes 74% premium stock sale with warrants
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.tc pixel
See More Mangoceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mangoceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mangoceuticals and other key companies, straight to your email.

About Mangoceuticals

Mangoceuticals (NASDAQ:MGRX) is a telehealth and men’s wellness company that provides online access to treatments and products focused primarily on sexual health, hair care and related wellness needs. The company markets its services directly to consumers through its digital platform, where customers can complete an online health assessment and, when appropriate, receive a prescription from a licensed medical provider.

Its product offerings have included MangoRx, a branded oral treatment for erectile dysfunction formulated with prescription ingredients such as tadalafil and sildenafil, as well as products and programs addressing hair loss and testosterone-related concerns. Mangoceuticals also offers nonprescription wellness products and personalized treatment options intended to support men’s health.

The company primarily serves customers in the United States through its online platform and relies on third-party pharmacies and healthcare providers to support prescription fulfillment and clinical services. Its Nasdaq-listed securities trade under the symbol MGRX. Treatment availability may vary by state and is subject to applicable medical and regulatory requirements.

View Mangoceuticals Profile